Prescription Digital Therapeutics for Mental Health: What FDA Clearance Does and Does Not Mean

A prescription digital therapeutic that clears FDA review has met a specific, limited bar: it was judged similar enough to a device already on the market to reach patients through the 510(k) pathway, not proven effective through the independent review a drug approval requires. Rejoyn, cleared in April 2024 as the first prescription digital therapeutic for major depressive disorder, is a useful case study because almost every phrase in its label rewards a second look.

Key points#

• FDA "clearance" through 510(k) rests on substantial equivalence to an existing device, which is a lower bar than the "approval" that drugs and higher-risk devices must clear.
• Rejoyn is authorized only as an add-on to antidepressant medication and clinician care for adults 22 and older, not as a standalone treatment and not as a cure.
• In its pivotal trial, the pre-specified primary endpoint narrowly missed the usual significance threshold; a supportive analysis crossed it.
• The word "adjunct" is doing real work: the trial asked whether adding the app helps, not whether it can replace medication or therapy.

Cleared and approved are different legal categories#

The FDA uses these two verbs deliberately, and the gap between them is regulatory rather than stylistic. Most software-based medical devices reach the market by being "cleared" through the 510(k) route, in which the maker shows the product is substantially equivalent to a legally marketed device, known as a predicate. Higher-risk devices are "approved" through premarket approval, which demands an independent showing of safety and effectiveness. Drugs travel a separate approval process entirely. Rejoyn was cleared, which means the central question its maker answered was whether it shares a predicate's intended use and is about as safe and effective as that predicate, not whether it works when measured from scratch. Calling a cleared device "FDA approved" moves it into the wrong category, and for medical devices that mislabeling is legally meaningful, not a matter of loose wording.

Inside the pivotal trial#

Rejoyn's clearance leaned on the Mirai study, also called CT-152, a 13-week, fully remote, double-blind randomized controlled trial later published in the Journal of Affective Disorders. It enrolled 386 adults aged 22 to 64 with major depressive disorder who were already taking antidepressants, then assigned them to either the active program or a sham app built to look and feel much like it. The active course ran six weeks, followed by a four-week window for follow-up. The pre-specified primary outcome was the change on the Montgomery-Asberg Depression Rating Scale, or MADRS, from the start to week six.

The numbers that rarely reach a headline are the ones worth sitting with. MADRS scores dropped by 9.03 points in the Rejoyn group and 7.25 points in the sham group. The 1.78-point difference carried a p-value of 0.0568, which falls just short of the customary 0.05 cutoff, so the primary comparison did not reach conventional statistical significance. A supportive analysis of the full randomized sample found a 2.12-point difference with a p-value of 0.0211, which does clear the line. Both figures sit in the peer-reviewed report, and a fair reading keeps both in view rather than quoting whichever one flatters the conclusion you arrived with.

What the sham group tells you#

The control arm is where the story sharpens. People using the sham app improved by more than seven MADRS points, a sizable shift by itself. That movement reflects several forces at once: the antidepressant these participants were already taking, the clinician care surrounding them, the natural rise and fall of a depressive episode, and the ordinary lift that comes from using a daily tool while expecting to feel better. A well-designed digital sham accounts for most of those forces. What is left over, the slice you can attribute to Rejoyn's specific cognitive exercises, came to roughly two MADRS points. That is a modest signal, and it explains why the primary endpoint landed on the edge of significance. Safety looked reassuring: the trial reported no adverse events attributed to the app, which is a real merit of software-based therapeutics as a class.

Why "adjunct" carries the weight#

The authorized use is adjunctive, meaning it is layered on top of ongoing antidepressant treatment and clinician oversight in adults 22 and older. The manufacturer states that Rejoyn is not meant to stand alone or to replace medication. So the trial answered one narrow question well: does adding this program to existing drug treatment help somewhat? It did not test whether the app could substitute for medication, stand in for psychotherapy, or help people who are not already under a clinician's care. Marketing language such as "clinically validated" and "first authorized" is accurate and also easy to over-read. Those phrases describe a regulatory first and a directional benefit, not a cure and not a reason for you to alter or stop a prescription.

A short checklist for any digital therapeutic#

A handful of questions separate the evidence from the packaging, and you can carry them well beyond one product:

• Was it cleared or approved, and through which pathway?
• Is it authorized to stand alone or only as an add-on, and for which age group and condition?
• Did the pre-specified primary endpoint succeed, or does the strongest figure come from a secondary or supportive analysis?
• What was the comparator: an active sham that mimics the real experience, or a waitlist that does not?
• Is the effect clinically meaningful, or merely detectable because the sample was large?
• How durable is it? A benefit at six weeks says little about six months.

None of this makes prescription digital therapeutics unimportant. A safe, scalable tool that adds a couple of points of symptom relief on top of standard care can genuinely help, especially in places where access to psychotherapy is thin. The work is simply to match your expectations to the evidence rather than to the label. Careful reading of trial endpoints and comparators is part of the everyday craft of evidence-based practice, and it applies to a depression app the same way it applies to a new pill.